Form 4: Checkpoint Therapeutics CFO Sells Shares to Cover Tax Obligations

Checkpoint Therapeutics' Chief Financial Officer, William Garrett Gray, sold 268,432 shares of common stock to cover tax obligations related to vesting restricted stock.

Summary

• William Garrett Gray, the Chief Financial Officer of Checkpoint Therapeutics, sold 268,432 shares of common stock on December 18, 2024.
• The sale was executed at a weighted average price of $4.01 per share, with individual prices ranging from $3.83 to $4.14.
• This transaction was automatically triggered by the vesting of 629,000 restricted stock shares and was intended to cover Mr. Gray's tax withholding obligations.
• Mr. Gray had no discretion over the sale, which was conducted by the company's restricted stock administrator according to company policy.
• Following the transaction, Mr. Gray beneficially owns 1,032,754 shares of common stock, including restricted shares that vest over time.

Sentiment

Score: 5

Explanation: The document describes a routine transaction related to executive compensation and tax obligations. It does not indicate any positive or negative sentiment regarding the company's performance.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's performance or outlook.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across publicly traded companies.
• The sale was executed automatically by the company's restricted stock administrator, which is a standard procedure to ensure compliance with insider trading regulations.
• The price range of $3.83 to $4.14 is within the expected range for a stock sale of this nature.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on the stock price, but it is not expected to be significant.
• The transaction is a normal part of executive compensation and does not indicate any change in the company's outlook.

Key Dates

Keywords

Checkpoint Therapeutics, William Garrett Gray, CFO, stock sale, tax obligations, restricted stock, insider trading, SEC Form 4